[go: up one dir, main page]

AU2001269923A1 - Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases - Google Patents

Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases

Info

Publication number
AU2001269923A1
AU2001269923A1 AU2001269923A AU6992301A AU2001269923A1 AU 2001269923 A1 AU2001269923 A1 AU 2001269923A1 AU 2001269923 A AU2001269923 A AU 2001269923A AU 6992301 A AU6992301 A AU 6992301A AU 2001269923 A1 AU2001269923 A1 AU 2001269923A1
Authority
AU
Australia
Prior art keywords
therapy
small molecule
lysosomal storage
storage diseases
enzyme replacement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001269923A
Inventor
Seng H Cheng
David Meeker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AU2001269923A1 publication Critical patent/AU2001269923A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2001269923A 2000-06-19 2001-06-19 Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases Abandoned AU2001269923A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21237700P 2000-06-19 2000-06-19
US60/212,377 2000-06-19
PCT/US2001/019579 WO2001097829A2 (en) 2000-06-19 2001-06-19 Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases

Publications (1)

Publication Number Publication Date
AU2001269923A1 true AU2001269923A1 (en) 2002-01-02

Family

ID=22790749

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001269923A Abandoned AU2001269923A1 (en) 2000-06-19 2001-06-19 Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases

Country Status (3)

Country Link
US (4) US20020095135A1 (en)
AU (1) AU2001269923A1 (en)
WO (1) WO2001097829A2 (en)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
GB9909066D0 (en) * 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
WO2002055064A2 (en) * 2001-01-12 2002-07-18 Oxford Glycosciences (Uk) Ltd. Mucopolysaccharidosis therapies
US20050032841A1 (en) * 1999-04-20 2005-02-10 Steven Walkley Therapeutic compositions and methods of treating glycolipid storage related disorders
BR0108077A (en) 2000-02-04 2002-10-22 Children S Hospital Res Founda Process for reducing atherosclerotic plaques in a mammal, method for treating atherosclerosis in a mammal, composition, methods for providing biologically active lipid hydrolyzing protein or polypeptide or mixture thereof, for cells of a mammal having biologically hydrolyzing lipid protein or polypeptide active, to provide biologically active lysosomal acid lipase to cells of a mammal having biologically active lysosomal acid lipase deficiency, to provide biologically active lysosomal acid lipase to cells of a mammal with atherosclerosis, to treat wolman's disease in a mammal , for treatment of cholesterol ester storage disease in a mammal, and for treatment of atherosclerosis in a mammal
US20020095135A1 (en) 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en) * 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US20020142299A1 (en) * 2001-01-09 2002-10-03 Davidson Beverly L. PTD-modified proteins
US8241622B2 (en) * 2001-07-13 2012-08-14 University Of Iowa Research Foundation Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences
EP1336411A1 (en) * 2002-02-14 2003-08-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Compositions and methods for improving enzyme replacement therapy of lysosomal storage diseases
AU2003223780A1 (en) * 2002-04-30 2003-11-17 University Of Florida Treatment for pompe disease
AU2003302724A1 (en) * 2002-08-13 2004-07-09 Mcivor, Scott, R. Methods of using vectors to treat metabolic disorders
DK1589993T3 (en) 2003-01-31 2015-03-09 Sinai School Medicine COMBINATION THERAPY FOR TREATMENT OF PROTEIN FAILURE DISORDERS
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
WO2005123055A2 (en) * 2004-06-14 2005-12-29 Musc Foundation For Research Development Methods for treating inflammatory disorders
CA2612538C (en) * 2005-05-17 2015-06-30 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
CA2633066C (en) * 2005-12-15 2015-01-20 Chemgen Corporation Enzymes for reduced immunological stress
ES2391657T3 (en) 2006-02-07 2012-11-28 Shire Human Genetic Therapies, Inc. Stabilized protein compositions that have a free thiol moiety
AU2008334094B2 (en) 2007-11-29 2015-01-22 Neuraltus Pharmaceuticals, Inc. Compositions and methods for treating lysosomal disorders
JP2011511007A (en) * 2008-02-01 2011-04-07 ザ スクリプス リサーチ インスティチュート Methods for treating conditions characterized by dysfunction of protein homeostasis
US20110189710A1 (en) * 2008-03-12 2011-08-04 Amicus Therapeutics, Inc. TREATMENT OF POMPE DISEASE WITH SPECIFIC PHARMACOLOGICAL CHAPERONES AND MONITORING TREATMENT USING SURROGATE MARkERS
CA3004867C (en) 2008-06-26 2020-09-15 Orphazyme Aps Use of hsp70 as a regulator of enzymatic activity
MX2011006347A (en) 2008-12-16 2011-09-06 Genzyme Corp Oligosaccharide-protein conjugates.
EP2411526A4 (en) * 2009-03-27 2012-09-19 Zacharon Pharmaceuticals Inc Ganglioside biosynthesis modulators
MX379016B (en) * 2009-07-28 2025-03-10 Takeda Pharmaceuticals Co COMPOSITIONS AND METHODS FOR TREATING GAUCHER'S DISEASE.
DK3482767T3 (en) 2009-08-28 2021-12-20 Icahn School Med Mount Sinai DOSAGE RECEPTION ENZYMER SUBSTITUTE TO TREAT ACID SPHINGOMYELINASE DEFICIENCY
EP3028701B1 (en) * 2009-11-17 2019-11-13 Baylor Research Institute 1-deoxygalactonojirimycin for use in treating a cardiac disease
US8765698B2 (en) * 2010-02-03 2014-07-01 University Of Central Florida Research Foundation, Inc. Methods and products for reawakening retrocyclins
HUE033217T2 (en) 2010-04-23 2017-11-28 Alexion Pharma Inc Lysosomal storage disease enzyme
US9453847B2 (en) 2010-07-19 2016-09-27 Shire Human Genetic Therapies, Inc. Mannose receptor C type 1 (MRC1) codon optimized cell line and uses thereof
ME02062B (en) 2010-09-09 2015-05-20 Synageva Biopharma Corp Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
JP2013544263A (en) 2010-11-30 2013-12-12 オルファザイム エーピーエス Method for increasing intracellular activity of Hsp70
EP2675472A4 (en) 2011-02-15 2014-09-17 Synageva Biopharma Corp Methods for treating lysosomal acid lipase deficiency
WO2012112677A2 (en) * 2011-02-15 2012-08-23 Children's Hospital Medical Center Methods for treating lysosomal acid lipase deficiency
CN117205331A (en) 2011-04-29 2023-12-12 西莱克塔生物科技公司 Tolerogenic synthetic nanocarriers for reducing antibody responses
EP2721151B1 (en) 2011-06-20 2017-12-06 Mount Sinai School Of Medicine Anti-tnf-therapy for the mucopolysaccharidoses and other lysosomal disorders
CA2865614A1 (en) 2012-03-02 2013-09-06 Shire Human Genetic Therapies, Inc. Compositions and methods for treating type iii gaucher disease
KR20140135222A (en) 2012-03-07 2014-11-25 아미쿠스 세라퓨틱스, 인코포레이티드 High concentration alpha-glucosidase compositions for the treatment of pompe disease
SI2844279T1 (en) 2012-05-03 2021-04-30 Amicus Therapeutics, Inc. Dosing regimens for the treatment of pompe disease
US10155027B2 (en) 2012-07-17 2018-12-18 Amicus Therapeutics, Inc. Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
CA2917995C (en) 2012-07-17 2021-01-26 Amicus Therapeutics, Inc. Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation
EP2914281A1 (en) 2012-11-05 2015-09-09 Genzyme Corporation Compositions and methods for treating proteinopathies
CN110639024A (en) 2013-05-03 2020-01-03 西莱克塔生物科技公司 Methods and compositions for enhancing CD4+ regulatory T cells
BR112017001601A2 (en) 2014-09-07 2017-11-21 Selecta Biosciences Inc methods and compositions for attenuating immune responses of the modulating antiviral transfer vector of gene expression
JP6678676B2 (en) 2014-09-15 2020-04-08 オーファザイム エー／エス Arimoclomol formulation
HUE070443T2 (en) 2014-09-30 2025-06-28 Amicus Therapeutics Inc Highly potent acid alpha-glucosidase with enhanced carbohydrates
JP6650943B2 (en) 2014-12-22 2020-02-19 コデクシス， インコーポレイテッド Human α-galactosidase variant
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
AU2016381832B2 (en) 2015-12-30 2024-01-25 Amicus Therapeutics, Inc. Augmented acid alpha-glucosidase for the treatment of Pompe disease
US11702672B2 (en) 2016-02-08 2023-07-18 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
US11684679B2 (en) 2016-03-07 2023-06-27 University Of Iowa Research Foundation AAV-mediated expression using a synthetic promoter and enhancer
CA3018745A1 (en) * 2016-03-25 2017-09-28 Genzyme Corporation Biomarkers of proteopathies and uses thereof
WO2017173059A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Method for selection of high m6p recombinant proteins
KR102618519B1 (en) 2016-03-30 2023-12-28 아미쿠스 세라퓨틱스, 인코포레이티드 Formulations comprising recombinant acid alpha-glucosidase
EP3442530A1 (en) 2016-04-13 2019-02-20 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
PT3448382T (en) 2016-04-29 2020-11-20 Orphazyme As C/O Cobis As Arimoclomol for treating glucocerebrosidase associated disorders
CN109152342A (en) * 2016-05-12 2019-01-04 布赖恩.P.汉利 CRISPR and other gene therapies safely delivered to most somatic cells in humans and animals
WO2017205739A1 (en) 2016-05-26 2017-11-30 University Of Iowa Research Foundation cis AND trans REQUIREMENTS FOR TERMINAL RESOLUTION OF HUMAN BOCAVIRUS 1
NL2017294B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Natural cryptic exon removal by pairs of antisense oligonucleotides.
MA43876B1 (en) * 2016-08-11 2019-04-30 Intrabio Ltd Pharmaceutical compositions and their uses against lysosomal storage diseases
WO2018046737A1 (en) * 2016-09-09 2018-03-15 Fondazione Telethon Combined therapy for mucopolysaccharidosis type vi (maroteaux-lamy-syndrome)
WO2018132747A1 (en) 2017-01-13 2018-07-19 University Of Iowa Research Foundation Bocaparvovirus small noncoding rna and uses thereof
MX2019010757A (en) 2017-03-11 2020-01-20 Selecta Biosciences Inc METHODS AND COMPOSITIONS RELATED TO THE COMBINED TREATMENT WITH ANTI-INFLAMMATORY AND SYNTHETIC NANPORTERS THAT INCLUDE AN IMMUNOSUPPRESSOR.
EP3624831B1 (en) 2017-05-15 2023-03-29 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase
BR112019025888A2 (en) 2017-06-07 2020-06-30 Regeneron Pharmaceuticals, Inc. polynucleotide encoding a therapeutic multi-domain protein, gene therapy vector, recombinant multi-domain therapeutic protein, expression method, methods to reduce the accumulation of glycogen in a tissue in a patient in need, to reduce the accumulation of glycogen in a tissue in a patient in need and to treat enzyme deficiency in a patient in need and / or tolerate the patient to the enzyme for which he is deficient, anti-cd63 antibody or antigen binding fragment, and pharmaceutical composition
AU2019218892B2 (en) 2018-02-07 2025-08-14 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
SG11202011232VA (en) 2018-05-17 2020-12-30 Regeneron Pharma Anti-cd63 antibodies, conjugates, and uses thereof
BR112021000830A2 (en) * 2018-07-18 2021-04-13 Regenxbio Inc. TREATMENT OF MUCOPOLYSACARIDOSIS I WITH ALUMINUM-L-IDURONIDASE (IDUS) HUMAN TOTALLY HUMAN AND GLYCOSILATED
MY207075A (en) 2018-12-20 2025-01-28 Codexis Inc Human alpha-galactosidase variants
IL303026A (en) 2020-11-19 2023-07-01 Zevra Denmark As Processes for preparing arimoclomol citrate and its intermediates
US20250163457A1 (en) * 2022-02-25 2025-05-22 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus for treating pompe disease with long term cessation of gaa enzyme replacement therapy

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851991A (en) * 1987-08-31 1998-12-22 The Regents Of The University Of California Therapeutic use of the retinoblastoma susceptibility gene product
US5549892A (en) * 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5236838A (en) * 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5179023A (en) * 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5272071A (en) * 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5236938A (en) * 1991-04-30 1993-08-17 Rhone-Poulenc Inc. Pesticidal 1-aryl-5-(substituted alkylideneimino)pyrazoles
US5968502A (en) * 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
JP3285355B2 (en) * 1992-06-04 2002-05-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Methods and compositions for in vivo gene therapy
US5834266A (en) * 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US5836905A (en) * 1994-06-20 1998-11-17 Lemelson; Jerome H. Apparatus and methods for gene therapy
US5767099A (en) * 1994-12-09 1998-06-16 Genzyme Corporation Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
US5840710A (en) * 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US5747471A (en) * 1994-12-09 1998-05-05 Genzyme Corporation Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules
US5948767A (en) * 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US5910487A (en) * 1994-12-09 1999-06-08 Genzyme Corporation Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
US5650096A (en) * 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5939401A (en) * 1994-12-09 1999-08-17 Genzyme Corporation Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
US5719131A (en) * 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
US5707618A (en) * 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
EP0850313B8 (en) 1995-09-08 2009-07-29 Genzyme Corporation Improved aav vectors for gene therapy
WO1997010817A1 (en) * 1995-09-20 1997-03-27 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US5840702A (en) * 1996-03-22 1998-11-24 Uab Research Foundation Cystic fibrosis treatment
US5935936A (en) * 1996-06-03 1999-08-10 Genzyme Corporation Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules
IL128036A (en) * 1996-07-15 2005-08-31 Univ Amsterdam Deoxynojirimycin derivatives comprising a polyclic alcohol group, pharmaceutical composition comprising a deoxynojirimycin derivative and uses thereof
PL190041B1 (en) 1996-09-13 2005-10-31 Transkaryotic Therapies Therapy against alpha-galactosidase a deficiency
US5861397A (en) * 1996-10-03 1999-01-19 Vical Incorporated Piperazine based cytofectins
US5925628A (en) * 1997-03-31 1999-07-20 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5912239A (en) * 1997-04-04 1999-06-15 Genzyme Corporation Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
US5948925A (en) * 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US5942634A (en) * 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
EP2147681A1 (en) * 1997-10-29 2010-01-27 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
US6465488B1 (en) * 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
JP2002538758A (en) 1998-02-17 2002-11-19 ジェンザイム・コーポレイション Method for producing pseudo adenovirus vector
US6303371B1 (en) 1998-02-17 2001-10-16 Genzyme Corporation Method of purified rAAV vector production in non-human cell line transfected with cocksackie and adenovirus receptor
WO1999057296A1 (en) 1998-05-01 1999-11-11 Genzyme Corporation Partially deleted adenoviral vectors
US6610703B1 (en) * 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
GB9909064D0 (en) 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
GB0100889D0 (en) * 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
GB9909066D0 (en) * 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
DE60001745T2 (en) * 1999-07-26 2004-03-04 G.D. Searle & Co., Chicago USE OF LONG-CHAIN N-ALKYL DERIVATIVES OF DEOXYNOJIRIMYCIN WITH GLUCOCEREBROSIDASE ENZYMES FOR PRODUCING A MEDICINE FOR TREATING DISEASES RELATING TO GLYCOLIPID ACCUMULATION
ES2284545T3 (en) * 1999-11-16 2007-11-16 Genzyme Corporation VECTORS AND TRANSGINS WITH REGULATING ELEMENTS FOR THE ADMINISTRATION OF LIVER GENES.
US20010031741A1 (en) * 2000-02-17 2001-10-18 Robin Ziegler Methods for treatment of lysosomal storage diseases
US20020095135A1 (en) 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
DK1589993T3 (en) * 2003-01-31 2015-03-09 Sinai School Medicine COMBINATION THERAPY FOR TREATMENT OF PROTEIN FAILURE DISORDERS

Also Published As

Publication number Publication date
US7910545B2 (en) 2011-03-22
WO2001097829A3 (en) 2002-12-27
WO2001097829A2 (en) 2001-12-27
US20110142818A1 (en) 2011-06-16
US8168587B2 (en) 2012-05-01
US20120183502A1 (en) 2012-07-19
US20070280925A1 (en) 2007-12-06
US20020095135A1 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
AU2001269923A1 (en) Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
EP1463512A4 (en) Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
AU2001280767A1 (en) Peptide-mediated delivery of molecules into cells
AU3818300A (en) Treating hair by targeting enzymes
AU2001245987A1 (en) Compositions and methods for gene therapy
AU2001227900A1 (en) Drug metabolizing enzymes
AU2001236713A1 (en) Methods for treatment of lysosomal storage diseases
AUPR311601A0 (en) Matrix gene expression in chondrogenesis
AU2001274981A1 (en) Drug metabolizing enzymes
AUPQ262599A0 (en) Gene expression
AU2001270303A1 (en) Drug metabolizing enzymes
AU2002312624A1 (en) Drug metabolizing enzymes
AU7709300A (en) Drug discovery using gene expression profiling
AU2001255324A1 (en) Drug metabolizing enzymes
AU2001235000A1 (en) Drug metabolizing enzymes
AU2732000A (en) Reverse gene therapy
AU1194201A (en) Fluorotellurite, amplifier glasses
AU2153401A (en) Gene expression in biological conditions
AU2001247444A1 (en) Erbeta-mediated gene expression
AU2001278154A1 (en) Drug metabolizing enzymes
AU2352301A (en) Gene expression in corneal diseases
AU4144600A (en) Cyp2a6 gene judgment methods
AU2001284680A1 (en) Haplotypes of the alas2 gene
AU4552700A (en) Gene therapy
AU2002230890A1 (en) Targeted enzyme prodrug therapy